# Ultromics secures £10 million investment to bring AI heart diagnostics to hospitals
Author:  Pal Sinha, Barnali 
Author URL: https://financedigest.com/author/pal-sinha-barnali
Published: 2018-05-29
Category: TECHNOLOGY
Category URL: https://financedigest.com/category/technology
Meta Title: Ultromics Raises £10 Million for AI Heart Disease Diagnosis
Meta Description: Discover how Ultromics is revolutionising the diagnosis of coronary heart disease with their Topological Analysis technology, reducing errors by 75%.
URL: https://financedigest.com/ultromics-secures-10-million-investment-to-bring-ai-heart-diagnostics-to-hospitalshtml

![undefined](https://prod.superblogcdn.com/site_cuid_cm5qst7v3003gwirgwqtxn8i8/images/fd250518-5-1736842696674-compressed.jpg)

Ultromics, the UK start-up behind breakthrough artificial intelligence (AI) technology for the diagnosis of coronary heart disease, has raised £10 million in Series-A investment. The funding was led by Oxford Sciences Innovation (OSI), with Neptune, RT Ventures, GT Healthcare, Tanarra, Fushia and personal investors Andre Crawford-Brunt and Dieter Spälti also participating.

Ultromics, which was founded in May 2017 as a spin out of Oxford University, has developed echocardiography analysis technology called Topological AnalysisTM  that aims to reduce diagnostic errors by 75%, which would significantly increase accuracy for diagnosing coronary artery disease in one of the most widely used diagnostic tests. The [technology was recently](https://www.financedigest.com/recent-technological-advancements-to-propel-growth-of-the-sesame-oil-market-in-foreseeable-future.html "Recent Technological Advancements to Propel Growth of the Sesame Oil Market in Foreseeable Future") selected by the American Society of Echocardiography for the 2018 Echovation Honor Role.

The AI algorithm was created by CEO and founder Ross Upton and is [currently being evaluated in a major](https://www.financedigest.com/cbd-gummies-market-current-scenario-and-industry-growth-forecast-with-major-key-players-data-2030.html "CBD Gummies Market| Current Scenario and Industry Growth Forecast with Major Key Players data 2030") multi-centre trial at six NHS hospitals overseen by co-founder Paul Leeson, Professor of Cardiovascular Medicine at the University of Oxford. The trial will be expanding to 20 NHS hospitals by the end of the [year giving](https://www.financedigest.com/bio-based-lubricants-to-give-a-push-to-the-global-pour-point-depressants-market-in-the-next-10-years-says-fmi.html "Bio-based Lubricants to Give a Push to the Global Pour Point Depressants Market in the Next 10 Years: Says FMI") clinicians an early chance to trial the new technology.

The £10 million investment is to be used to bring the [technology to market in the USA and make it available](https://www.financedigest.com/maximising-the-opportunities-available-from-marketing-technology-and-innovation-focused-thinking.html "Maximising the opportunities available from marketing technology and innovation focused thinking") in the UK early 2019. The company will also continue the research and development into new diagnostic [support products](https://www.financedigest.com/the-cancer-supportive-care-products-market-to-stay-innovatively-persistent.html "The Cancer Supportive Care Products Market to stay innovatively persistent") for cardiology, including heart screening technologies, valve disease, heart failure, heart muscle disease and cardiotoxicity.

Upton, who was recently honoured as one of Europe’s Top 100 founders by [SEI](https://sei.it/en/) Torino Forum, explains: “Our goal is to increase accuracy, consistency and efficiency in cardiology, providing patients with a reliable test and significant saving for healthcare systems worldwide. We’re delighted that we’ve [secured this funding so we can commercialize this exciting technology](https://www.financedigest.com/how-open-source-technology-is-securing-the-future-of-financial-services.html "How open-source technology is securing the future of financial services") and bring its benefits to patients everywhere.”

The company has recently made some [key additions to it’s world-class scientific](https://www.financedigest.com/covid-19-diagnostics-market-analysis-and-forecast-to-2030-leading-key-players-are-veredus-laboratories-thermo-fisher-scientific-quidel-perkin-elmer-neuberg-diagnostics-others.html "Covid-19 Diagnostics Market Analysis and Forecast to 2030 | Leading Key Players are: Veredus Laboratories, Thermo Fisher Scientific, Quidel, Perkin Elmer, Neuberg Diagnostics & Others") advisory board including: Dr Sanjiv Kaul (Head of Cardiovascular Medicine, OHSU) and Prof Michael Wooldridge (Head of Computer Science, University of Oxford). In addition, it has recently appointed Dr Helen Routh (former Senior VP at Royal Philips) as chairman and Dr Achim Mayer (former VP at TomTec) to head up [product development](https://www.financedigest.com/tire-recycling-downstream-products-market-to-observe-strong-development-by-2019-2027.html "Tire Recycling Downstream Products Market to Observe Strong Development by 2019-2027").

Heart disease affects almost 50 per cent of people over the age of 40 – making it the biggest killer globally. To diagnose heart disease, in most cases cardiologists rely on images created by echocardiograms – with over 60 million performed annually in the USA alone. They traditionally do this by assessing the images based on only a few factors. This means that in the best centres, echo tests used to detect coronary disease are only correct 80 per cent of the time. Therefore, there are many patients who have coronary disease that goes undiagnosed and many patients who are undergoing unnecessary diagnostic procedures.

Sir John Bell, Regius Professor of Medicine at Oxford added: “ Identifying individuals at high risk when they have coronary heart disease is a challenge. By using the huge amount of extra and smart [information offered up by AI systems](https://www.financedigest.com/the-cardiovascular-information-systems-market-is-expected-to-grow-on-a-persistent-note-in-the-future.html "The Cardiovascular Information Systems Market is expected to grow on a persistent note in the future"), we can identify people at risk, diagnose medical problems earlier and more precisely and identify who will benefit from what interventions. Ultromics is an exciting company to [watch in this space and a good example of how industry](https://www.financedigest.com/online-valuation-tool-is-the-new-face-of-the-pre-owned-watch-industry.html "Online valuation tool is the new face of the pre-owned watch industry") and the NHS can work together effectively, which is a key goal of the UK’s Life Science Industrial Strategy


---
This blog is powered by Superblog. Visit https://superblog.ai to know more.
---

